1
|
O'Rahelly M, Fernandez-Garcia M, Hahn A, Nguyen C, Kim D, Byun S, Koelbel H, Schara U, Henrich M, Leslie J, Eymard B, Chouchane M, Roefke K, Thieme A, van den Bergh P, Paquay S, Schneider-Gold C, Vincent A, Allen N, Jungbluth H. P.379Fetal Acetylcholine Receptor Inactivation Syndrome (FARIS): A potentially treatable autoimmune disorder mimicking a wide range of genetic neuromuscular conditions. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
2
|
de Rougemont A, Kaplon J, Fremy C, Legrand-Guillien MC, Minoui-Tran A, Payan C, Vabret A, Mendes-Martins L, Chouchane M, Maudinas R, Huet F, Dubos F, Hober D, Lazrek M, Bouquignaud C, Decoster A, Alain S, Languepin J, Gillet Y, Lina B, Mekki Y, Morfin-Sherpa F, Guigon A, Guinard J, Foulongne V, Rodiere M, Avettand-Fenoel V, Bonacorsi S, Garbarg-Chenon A, Gendrel D, Lebon P, Lorrot M, Mariani P, Meritet JF, Schnuriger A, Agius G, Beby-Defaux A, Oriot D, Colimon R, Lagathu G, Mory O, Pillet S, Pozzetto B, Stephan JL, Aho S, Pothier P. Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France. Clin Microbiol Infect 2016; 22:737.e9-737.e15. [PMID: 27287887 DOI: 10.1016/j.cmi.2016.05.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 05/25/2016] [Accepted: 05/28/2016] [Indexed: 11/18/2022]
Abstract
Group A rotavirus (RVA) is the leading cause of acute gastroenteritis in young children worldwide. A prospective surveillance network has been set up to investigate the virological and clinical features of RVA infections and to detect the emergence of potentially epidemic strains in France. From 2009 to 2014, RVA-positive stool samples were collected from 4800 children <5 years old attending the paediatric emergency units of 16 large hospitals. Rotaviruses were then genotyped by RT-PCR with regard to their outer capsid proteins VP4 and VP7. Genotyping of 4708 RVA showed that G1P[8] strains (62.2%) were predominant. The incidence of G9P[8] (11.5%), G3P[8] (10.4%) and G2P[4] (6.6%) strains varied considerably, whereas G4P[8] (2.7%) strains were circulating mostly locally. Of note, G12P[8] (1.6%) strains emerged during the seasons 2011-12 and 2012-13 with 4.1% and 3.0% prevalence, respectively. Overall, 40 possible zoonotic reassortants, such as G6 (33.3%) and G8 (15.4%) strains, were detected, and were mostly associated with P[6] (67.5%). Analysis of clinical records of 624 hospitalized children and severity scores from 282 of them showed no difference in clinical manifestations or severity in relation to the genotype. The relative stability of RVA genotypes currently co-circulating and the large predominance of P[8] type strains may ensure vaccine effectiveness in France. The surveillance will continue to monitor the emergence of new reassortants that might not respond to current vaccines, all the more so as all genotypes can cause severe infections in infants.
Collapse
Affiliation(s)
- A de Rougemont
- Centre National de Référence des virus entériques, Laboratoire de Virologie, CHU de Dijon, France; UFR des Sciences de Santé, Université de Bourgogne, Dijon, France.
| | - J Kaplon
- Centre National de Référence des virus entériques, Laboratoire de Virologie, CHU de Dijon, France
| | - C Fremy
- Centre National de Référence des virus entériques, Laboratoire de Virologie, CHU de Dijon, France
| | | | | | - C Payan
- Centre Hospitalier Universitaire de Brest, France
| | - A Vabret
- Centre Hospitalier Universitaire de Caen, France
| | | | - M Chouchane
- Centre Hospitalier Universitaire de Dijon, France
| | - R Maudinas
- Centre Hospitalier Universitaire de Dijon, France
| | - F Huet
- UFR des Sciences de Santé, Université de Bourgogne, Dijon, France; Centre Hospitalier Universitaire de Dijon, France
| | - F Dubos
- Centre Hospitalier Régional Universitaire de Lille, France
| | - D Hober
- Centre Hospitalier Régional Universitaire de Lille, France
| | - M Lazrek
- Centre Hospitalier Régional Universitaire de Lille, France
| | - C Bouquignaud
- Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | - A Decoster
- Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | - S Alain
- Centre Hospitalier Universitaire de Limoges, France
| | - J Languepin
- Centre Hospitalier Universitaire de Limoges, France
| | | | - B Lina
- Hospices Civils de Lyon, France
| | - Y Mekki
- Hospices Civils de Lyon, France
| | | | - A Guigon
- Centre Hospitalier Universitaire d'Orléans, France
| | - J Guinard
- Centre Hospitalier Universitaire d'Orléans, France
| | - V Foulongne
- Centre Hospitalier Universitaire de Montpellier, France
| | - M Rodiere
- Centre Hospitalier Universitaire de Montpellier, France
| | | | - S Bonacorsi
- Assistance Publique Hôpitaux de Paris, France
| | | | - D Gendrel
- Assistance Publique Hôpitaux de Paris, France
| | - P Lebon
- Assistance Publique Hôpitaux de Paris, France
| | - M Lorrot
- Assistance Publique Hôpitaux de Paris, France
| | - P Mariani
- Assistance Publique Hôpitaux de Paris, France
| | - J-F Meritet
- Assistance Publique Hôpitaux de Paris, France
| | | | - G Agius
- Centre Hospitalier Universitaire de Poitiers, France
| | - A Beby-Defaux
- Centre Hospitalier Universitaire de Poitiers, France
| | - D Oriot
- Centre Hospitalier Universitaire de Poitiers, France
| | - R Colimon
- Centre Hospitalier Universitaire de Rennes, France
| | - G Lagathu
- Centre Hospitalier Universitaire de Rennes, France
| | - O Mory
- Centre Hospitalier Universitaire de Saint-Etienne, France
| | - S Pillet
- Centre Hospitalier Universitaire de Saint-Etienne, France
| | - B Pozzetto
- Centre Hospitalier Universitaire de Saint-Etienne, France
| | - J-L Stephan
- Centre Hospitalier Universitaire de Saint-Etienne, France
| | - S Aho
- Service d'Hygiène Hospitalière, Centre Hospitalier Universitaire de Dijon, France
| | - P Pothier
- Centre National de Référence des virus entériques, Laboratoire de Virologie, CHU de Dijon, France; UFR des Sciences de Santé, Université de Bourgogne, Dijon, France
| |
Collapse
|
3
|
Thevenon J, Duffourd Y, Masurel-Paulet A, Lefebvre M, Feillet F, El Chehadeh-Djebbar S, St-Onge J, Steinmetz A, Huet F, Chouchane M, Darmency-Stamboul V, Callier P, Thauvin-Robinet C, Faivre L, Rivière JB. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet 2016; 89:700-7. [PMID: 26757139 DOI: 10.1111/cge.12732] [Citation(s) in RCA: 172] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 01/05/2016] [Accepted: 01/07/2016] [Indexed: 01/03/2023]
Abstract
The current standard of care for diagnosis of severe intellectual disability (ID) and epileptic encephalopathy (EE) results in a diagnostic yield of ∼50%. Affected individuals nonetheless undergo multiple clinical evaluations and low-yield laboratory tests often referred to as a 'diagnostic odyssey'. This study was aimed at assessing the utility of clinical whole-exome sequencing (WES) in individuals with undiagnosed and severe forms of ID and EE, and the feasibility of its implementation in routine practice by a small regional genetic center. We performed WES in a cohort of 43 unrelated individuals with undiagnosed ID and/or EE. All individuals had undergone multiple clinical evaluations and diagnostic tests over the years, with no definitive diagnosis. Sequencing data analysis and interpretation were carried out at the local molecular genetics laboratory. The diagnostic rate of WES reached 32.5% (14 out of 43 individuals). Genetic diagnosis had a direct impact on clinical management in four families, including a prenatal diagnostic test in one family. Our data emphasize the clinical utility and feasibility of WES in individuals with undiagnosed forms of ID and EE and highlight the necessity of close collaborations between ordering physicians, molecular geneticists, bioinformaticians and researchers for accurate data interpretation.
Collapse
Affiliation(s)
- J Thevenon
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - Y Duffourd
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - A Masurel-Paulet
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - M Lefebvre
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - F Feillet
- Service de Médecine Infantile 1, Centre de Référence des Maladies Héréditaires du Métabolisme, Centre Hospitalier Universitaire Brabois-Enfants, Vandœuvre-lès-Nancy, France
| | | | - J St-Onge
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - A Steinmetz
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - F Huet
- Service de Pédiatrie 1, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - M Chouchane
- Service de Pédiatrie 1, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - V Darmency-Stamboul
- Service de Pédiatrie 1, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - P Callier
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, Centre Hospitalier Universitaire Dijon, Dijon, France
| | - C Thauvin-Robinet
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - L Faivre
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - J B Rivière
- Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.,Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, Centre Hospitalier Universitaire Dijon, Dijon, France
| |
Collapse
|
4
|
Huet F, Chouchane M, Cremillieux C, Aubert M, Caulin E, Pothier P, Allaert FA. [Prospective epidemiological study of rotavirus gastroenteritis in Europe (REVEAL study). Results in the French area of the study]. Arch Pediatr 2008; 15:362-74. [PMID: 18396016 DOI: 10.1016/j.arcped.2008.01.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2007] [Revised: 12/08/2007] [Accepted: 01/04/2008] [Indexed: 11/16/2022]
Abstract
PRIMARY OBJECTIVE To estimate the incidence of acute gastroenteritis (AGE) and rotavirus acute gastroenteritis (RVAGE) in children less than 5 years of age seeking medical care in primary care, emergency department, and hospital settings. SECONDARY OBJECTIVES To compare the clinical profile of RVAGE and non-RVAGE and to describe the distribution of RV serotypes among RVAGE cases. METHODS A prospective primary care, emergency ward and hospital-based observational study was conducted during 1 year in a selected city of France with 250,000 inhabitants. Children less than 5 years of age presenting with symptoms of AGE were included. Rotavirus was identified using an Elisa test in stools. RESULTS The estimated annual incidence of RVAGE was 1.56% for AGE and 0.87% for RVAGE in hospital, 5.87% for AGE and 2.65% for RVAGE in emergency-wards, 7.39% for AGE and 1.45% for RVAGE in primary care. Total incidence was 14.82% for AGE and 4.96% for RVAGE among children less than 5 years of age. RVAGE were more clinically severe than the AGE: dehydration (26.8% vs. 14.7%, p<0.0001), vomiting 84.9% vs. 60.9%, p<0.0001), fever (74.3% vs. 44.4%, p<0.0001), lethargy (84.9% vs. 70.2%, p<0.0001). G9 serotype was the most frequent serotype encountered (54.7%) during the study period followed by G3 serotype (33.6%) and G2 serotype (7.9%). CONCLUSION In this study, RVAGE, caused by serotypes G9 and G3, represented about 1/3 of AGE and were more severe than non-RV AGE with twice as high dehydration rate. These results underline the need for continued promotion on the use of oral rehydration fluids and provide some arguments on the benefits of vaccination against rotavirus and also permanent virological monitoring of circulating serotypes.
Collapse
Affiliation(s)
- F Huet
- Service de pédiatrie, CHU de Dijon, Dijon, France
| | | | | | | | | | | | | |
Collapse
|
5
|
Csaszar Goutchkoff L, Chouchane M, De Monleon J, Perez-Martin S, Falcon-Eicher S, Bonnet C, Huet F. SFP-P020 – Divers – La maladie de Kawasaki chez l’enfant de moins de six mois. Arch Pediatr 2008. [DOI: 10.1016/s0929-693x(08)72155-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Jaboulet M, Chouchane M, Huet F. SFP-45 – Neurologie – Analyse de la prise en charge et du devenir des paralysies faciales périphériques de l’enfant. Arch Pediatr 2008. [DOI: 10.1016/s0929-693x(08)72112-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Chouchane M, Benouachkou-Debuche V, Giroud M, Durand C, Gouyon JB. [Agenesis of the corpus callosum: etiological and clinical aspects, diagnostic methods and prognosis]. Arch Pediatr 1999; 6:1306-11. [PMID: 10627903 DOI: 10.1016/s0929-693x(00)88894-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Agenesis of the corpus callosum is a frequent congenital malformation with many etiologies and clinical features. It can occur as an isolated defect which is usually sporadic, it is frequently associated with other malformations, genetic syndromes and metabolic disorders. Ante- or postnatal diagnosis must be followed by a careful search for etiology, and it raises uncertain and difficult question with regard to pregnancy continuation and infant development.
Collapse
Affiliation(s)
- M Chouchane
- Service de pédiatrie, Centre hospitalier Louis-Pasteur, Dole, France
| | | | | | | | | |
Collapse
|
8
|
Gouyon JB, Chouchane M, Françoise M. [Renal effects of prolonged indomethacin therapy in premature infants]. Arch Pediatr 1994; 1:894-7. [PMID: 7842069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Indomethacin therapy for large patent ductus arterious would be more effective when it is prescribed for 5 or 6 days vs 2 or 3 days. Effects on renal function of such prolonged therapy is still debated. PATIENTS AND METHODS Seven preterm infants (gestational age: 28.6 +/- 0.9 weeks; birth-weight: 1,169 +/- 267 g) with symptomatic patent ductus arterious were given indomethacin, 0.1 mg/kg/day for 6 days (four patients) and 5 days (three patients). Urinary water excretion, water output/input ratio, creatinine clearance and body weight were measured before and every day during therapy. RESULTS Urinary water excretion, water output/input ratio and creatinine clearance were significantly decreased after 5 days of treatment, -40 +/- 30%, -42 +/- 27% and -48 +/- 31%, respectively. Creatinemia and body weight were significantly increased, + 34 +/- 36% and + 9 +/- 7%, respectively. Mean sodium plasma level and fractional excretion of sodium, potassium and chloride remained stable. CONCLUSION Prolonged therapy with indomethacin does not avoid the renal side effects seen with shorter administration.
Collapse
Affiliation(s)
- J B Gouyon
- Service de pédiatrie 2, hôpital d'Enfants, Dijon, France
| | | | | |
Collapse
|
9
|
Nivelon JL, Chouchane M, Forest MG, Morel Y, Huet F, Nivelon-Chevallier A, François C. [Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 9 treated pregnancies]. Ann Pediatr (Paris) 1993; 40:421-5. [PMID: 7902059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Prenatal treatment based on administration of dexamethasone to the mother during pregnancy was initiated early during nine pregnancies with a high risk of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The purpose of this treatment was to prevent fetal virilization by reducing production of androgens by the adrenal glands. Prenatal diagnosis was achieved by comparing amniotic fluid cell HLA genotypes and more recently by subjecting trophoblasts to molecular genetic studies. Together with prenatal determination of fetal sex, this allowed to determine that only two female fetuses were affected. Efficacy of continued prenatal treatment in these two cases was good in one case and mediocre in the other. The treatment was well tolerated by the mothers and fetuses.
Collapse
|